No Data
Catalyst Watch: HP Enterprise Event, Walmart+ Week, Pure Storage Buzz, and Triple-witching Volatility
QIAGEN's Software QCI Interpret Accelerates Clinical Reporting Turnaround Time for High Throughput NGS Testing Labs
Express News | QIAGEN Launches 35 New Digital PCR Microbial DNA Detection Assays For QIAcuity Platform, Targeting Pathogens For Tropical Diseases, STIs, And UTIs, Enhancing Microbial Research Offerings
QIAGEN Launches New QIAcuity Digital PCR Assays for Microbial Applications, Enhancing Infectious Disease Research and Surveillance
Venlo, the Netherlands, June 11, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced the launch of 35 new wet-lab tested digital PCR Microbial DNA Detection Assays for its
Polymerase Chain Reaction (PCR) for Point-of-Care (POC) Diagnostics 2024-2029, With Profiles of Leading Market Players, Including Abbott, Danaher (Cepheid), Roche, Thermo-Fisher Scientific and QIAGEN - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Polymerase Chain Reaction (PCR) for Point-of-Care (POC) Diagnostics 2024-2029" report has been added to ResearchAndMarkets.com's offering.The global market for polymerase
Stifel Maintains Qiagen NV(QGEN.US) With Hold Rating, Cuts Target Price to $45
Stifel analyst Daniel Arias maintains $Qiagen NV(QGEN.US)$ with a hold rating, and adjusts the target price from $55 to $45.According to TipRanks data, the analyst has a success rate of 40.3% and a to